Antibody responses induced by trivalent inactivated influenza vaccine among pregnant and non-pregnant women in Thailand: A matched cohort study.
Adult
Antibodies, Viral
/ blood
Antibody Formation
/ immunology
Cohort Studies
Female
Humans
Influenza A virus
/ immunology
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ epidemiology
Pregnancy
Pregnant Women
Prospective Studies
Thailand
/ epidemiology
Vaccination
Vaccines, Inactivated
/ administration & dosage
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
03
2021
accepted:
21
05
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
16
11
2021
Statut:
epublish
Résumé
We compared influenza antibody titers among vaccinated and unvaccinated pregnant and non-pregnant women. During 1st June- 30th September 2018, four groups of cohort participants-vaccinated pregnant, unvaccinated pregnant, vaccinated non-pregnant, and unvaccinated non-pregnant women were selected by matching age, gestational age, and the week of vaccination. Serum antibody titers against each strain of 2018 Southern Hemisphere inactivated trivalent influenza vaccine (IIV3) were assessed by hemagglutination inhibition (HI) assay on Day 0 (pre-vaccination) and Day 28 (one month post-vaccination) serum samples. Geometric mean titer (GMT), GMT ratio (GMR), seroconversion (defined as ≥4 fold increase in HI titer), and seroprotection (i.e. HI titer ≥1:40) were compared across the study groups using multilevel regression analyses, controlling for previous year vaccination from medical records and baseline antibody levels. A total of 132 participants were enrolled in the study (33 in each of the four study groups). The baseline GMTs for influenza A(H1N1), A(H3N2), and B vaccine strains were not significantly different among all four groups (all p-values >0.05). After one month, both vaccinated groups had significantly higher GMT, GMR, seroconversion, and seroprotection than their unvaccinated controls (all p-values <0.05). The seroconversion rate was over 60% for any strain among the vaccinated groups, with the highest (88.8%) observed against A(H1N1) in the vaccinated pregnant group. Similarly, at least 75% of the vaccinated participants developed seroprotective antibody levels against all three strains; the highest seroprotection was found against A(H3N2) at 92.6% among vaccinated non-pregnant participants. Antibody responses (post-vaccination GMT, GMR, seroconversion, and seroprotection) were not significantly different between pregnant and non-pregnant women for all three strains of IIV3 (all p>0.05). The 2018 seasonal IIV3 was immunogenic against all three vaccine strains and pregnancy did not seem to alter the immune response to IIV3. These findings support the current influenza vaccination recommendations for pregnant women.
Sections du résumé
BACKGROUND
We compared influenza antibody titers among vaccinated and unvaccinated pregnant and non-pregnant women.
METHODS
During 1st June- 30th September 2018, four groups of cohort participants-vaccinated pregnant, unvaccinated pregnant, vaccinated non-pregnant, and unvaccinated non-pregnant women were selected by matching age, gestational age, and the week of vaccination. Serum antibody titers against each strain of 2018 Southern Hemisphere inactivated trivalent influenza vaccine (IIV3) were assessed by hemagglutination inhibition (HI) assay on Day 0 (pre-vaccination) and Day 28 (one month post-vaccination) serum samples. Geometric mean titer (GMT), GMT ratio (GMR), seroconversion (defined as ≥4 fold increase in HI titer), and seroprotection (i.e. HI titer ≥1:40) were compared across the study groups using multilevel regression analyses, controlling for previous year vaccination from medical records and baseline antibody levels.
RESULTS
A total of 132 participants were enrolled in the study (33 in each of the four study groups). The baseline GMTs for influenza A(H1N1), A(H3N2), and B vaccine strains were not significantly different among all four groups (all p-values >0.05). After one month, both vaccinated groups had significantly higher GMT, GMR, seroconversion, and seroprotection than their unvaccinated controls (all p-values <0.05). The seroconversion rate was over 60% for any strain among the vaccinated groups, with the highest (88.8%) observed against A(H1N1) in the vaccinated pregnant group. Similarly, at least 75% of the vaccinated participants developed seroprotective antibody levels against all three strains; the highest seroprotection was found against A(H3N2) at 92.6% among vaccinated non-pregnant participants. Antibody responses (post-vaccination GMT, GMR, seroconversion, and seroprotection) were not significantly different between pregnant and non-pregnant women for all three strains of IIV3 (all p>0.05).
CONCLUSIONS
The 2018 seasonal IIV3 was immunogenic against all three vaccine strains and pregnancy did not seem to alter the immune response to IIV3. These findings support the current influenza vaccination recommendations for pregnant women.
Identifiants
pubmed: 34106994
doi: 10.1371/journal.pone.0253028
pii: PONE-D-21-10606
pmc: PMC8189519
doi:
Substances chimiques
Antibodies, Viral
0
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0253028Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2018 Dec 18;36(52):8054-8061
pubmed: 30416018
BMC Med Res Methodol. 2010 Mar 08;10:18
pubmed: 20210985
J Infect Dis. 2015 Sep 15;212(6):861-70
pubmed: 25740957
J Infect Dis. 2011 May 1;203(9):1301-8
pubmed: 21459817
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
Influenza Other Respir Viruses. 2019 Nov;13(6):582-592
pubmed: 31419068
Vaccine X. 2019 Sep 17;3:100042
pubmed: 31660536
Vaccine. 2015 Jan 29;33(5):742-7
pubmed: 25454853
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Pediatr Infect Dis J. 2011 Dec;30(12):1081-5
pubmed: 21983214
Hum Vaccin Immunother. 2018 Mar 4;14(3):758-766
pubmed: 28708952
Clin Infect Dis. 2018 Jul 18;67(3):327-333
pubmed: 29471464
MMWR Recomm Rep. 2020 Aug 21;69(8):1-24
pubmed: 32820746
Obstet Gynecol. 2012 Mar;119(3):631-9
pubmed: 22353963
N Engl J Med. 2010 Apr 29;362(17):1644-6
pubmed: 20427817
Vaccines (Basel). 2020 Jun 19;8(2):
pubmed: 32575440
Influenza Other Respir Viruses. 2016 Jan;10(1):2-8
pubmed: 26439108
J Infect Dis. 2012 Dec 1;206(11):1670-3
pubmed: 22984116
Am J Perinatol. 2016 Sep;33(11):1104-14
pubmed: 27603545
Lancet. 2017 Feb 4;389(10068):571-572
pubmed: 28170335
Vaccine. 2016 Apr 19;34(18):2141-6
pubmed: 26854910
Vaccine. 2020 Sep 22;38(41):6478-6483
pubmed: 32868130
Vaccine. 2018 Jul 25;36(31):4734-4741
pubmed: 29941326
PLoS One. 2017 Jan 18;12(1):e0169221
pubmed: 28099486
Vaccine. 2021 Jan 3;39(1):18-25
pubmed: 33243634
Int J Infect Dis. 2020 Mar;92:1-12
pubmed: 31863875
Matern Child Health J. 2020 Feb;24(2):229-240
pubmed: 31865602
Vaccine. 2020 Jul 14;38(33):5355-5363
pubmed: 32571718